|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall survival was not different between patients with PD-L1+ vs PD-L1- anaplastic large cell lymphoma (p = 0.44), regardless of ALK status and International Prognostic Index (IPI) score.
|
31383967 |
2020 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A lymph node and bone marrow biopsy eventually revealed the presence of anaplastic lymphoma kinase+anaplastic large cell lymphoma.
|
30830032 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK(-) CD30(+) anaplastic large cell lymphoma is a type of non-Hodgkin lymphoma showing poor prognosis, and seldom co-occurs with sarcoidosis.
|
30909793 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, our findings suggest that CDK6 could be a therapeutic target for the development of future treatments for NPM-ALK<sup>+</sup> anaplastic large-cell lymphoma.
|
30262555 |
2019 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n = 50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n = 44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n = 23, 14.7%), ALCL ALK positive (n = 16, 10.3%), and other (n = 23, 14.7%).
|
29119842 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Case of ALK+ Anaplastic Large-Cell Lymphoma With Aberrant Myeloperoxidase Expression and Initial Cutaneous Presentation.
|
29905579 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Crizotinib induces apoptosis and gene expression changes in ALK+ anaplastic large cell lymphoma cell lines; brentuximab synergizes and doxorubicin antagonizes.
|
29697184 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, ALK rearrangements are also implicated in other malignancies, including anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors (IMTs).
|
29352732 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Involvement of oncogenic tyrosine kinase NPM-ALK in trifluoperazine-induced cell cycle arrest and apoptosis in ALK<sup>+</sup> anaplastic large cell lymphoma.
|
29086626 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary Gastric ALK-negative EBV-negative Anaplastic Large Cell Lymphoma Presenting with Iron Deficiency Anemia.
|
28652442 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The anaplastic lymphoma kinase (ALK) has been demonstrated to be a valid clinical target in diseases such as anaplastic large cell lymphoma and non-small cell lung cancer.
|
29855693 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Systemic anaplastic lymphoma kinase positive (ALK+) anaplastic large cell lymphoma with extranodal involvement (ALCL-E) is a rare form of non-Hodgkin lymphoma.
|
29602182 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epitope mapping of anti-ALK antibodies in children with anaplastic large cell lymphoma.
|
30077013 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anaplastic lymphoma kinase (ALK) gene activation is involved in the carcinogenesis process of several human cancers such as anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors and neuroblastoma, as a consequence of fusion with other oncogenes (NPM, EML4, TIM, etc) or gene amplification, mutation or protein overexpression.
|
29455642 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma.
|
29488330 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most common subtype was PTCL-not otherwise specified (35.7%), followed by anaplastic large cell lymphoma (ALCL), ALK negative (21.3%), natural killer/T cell lymphoma, angioimmunoblastic T-cell lymphoma (AITL), ALCL, ALK positive, hepatosplenic T cell lymphoma (HSTCL) and adult T cell leukaemia/lymphoma followed in frequency with 13.1, 11.5, 8.6, 8.2 and 1.6 per cent cases, respectively.
|
30082570 |
2018 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As suggested by its name, ALK was first described as part of a translocation product in cases of anaplastic large-cell lymphoma, with other genetic and cytogenetic ALK mutations subsequently coming to attention in the development of many other hematologic and solid organ malignancies.
|
28895885 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma.
|
27694894 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL).
|
29035291 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The anaplastic lymphoma kinase (ALK) gene was initially identified as a fusion partner of the nucleophosmin gene in anaplastic large-cell lymphoma with t(2;5)(p23;q35) translocation, and then described with different genetic abnormalities in a number of tumors.
|
28756644 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
|
28356514 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALK was first reported in 1994 as a translocation in anaplastic large cell lymphoma and then described with different abnormalities in a number of tumors.
|
28112990 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using various molecular technologies, we have characterized ALK fusions in eight recently diagnosed anaplastic large cell lymphoma cases with cytoplasmic-only ALK expression.
|
28659337 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Only few recurrent cytogenetic aberrations have been identified in the T-cell NHL and the best known is the ALK gene translocation t(2;5)(p23;q35) in anaplastic large cell lymphoma.
|
27910030 |
2017 |
|
Childhood Anaplastic Large Cell Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
|
28787259 |
2017 |